Skip to Main Content

Go to Main Navigation


Year Established:
Fairfax, VA, US
Company Type:
Small Business (1-10M TTM Revenue)
Professional Associates:

Immudex provides MHC Dextramers for the monitoring of antigen-specific T cells. Under an agreement with the US Cancer Immunotherapy Consortium (CIC) and the European Cancer Immunotherapy Consortium (CIMT), Immudex also provides MHC Multimer and Elispot proficiency panel services worldwide.
Immudex’s MHC Dextramer® products are utilized for the quantification or sorting of antigen-specific T cells in life science research, in vitro diagnostics, as well as the development of immunotherapeutics and vaccines. The primary focus is research-use-only products for the immune monitoring of immunotherapy development, and monitoring of CMV cellular immunity in transplant and other immune-deficient patients. In Europe, the CE-marked Dextramer CMV Kit is approved for in vitro diagnostic use, for the quantification of CMV-specific T cells.
Our soon-to-be released DNA tagged Dextramer reagents enable massive multiplexing of antigen-specific T cell detection. To date we have achieved quantitation of over 1000 CD8 T cell specificities in a single, small blood sample. To find out more about how Immudex is improving immune monitoring and enabling better treatment decisions please visit us at

To learn more about proficiency panel participation email

Site Badges
4031 University Drive Fairfax, VA, 22030 United States
Immudex, Aps
Bredevej 2A Virum, , DK-2830 Denmark

Get started

To request access, simply fill out the form below and we will contact you.

Password must:

• Be at least 12 characters in length

• Contain a lowercase letter (a-z)

• Contain an uppercase letter (A-Z)

• Contain a numeral (0-9)

• Contain a special character (%, $, !, @)